Piper Jaffray targets SLXP. January 10,2010. Piper Jaffray maintains an Overweight rating on Salix Pharmaceuticals (Nasdaq: SLXP), raises price target from $29 to $58. http://www.streetinsider.com/Analyst+Comments/Piper+Jaffray+Names+Salix+Pharmaceuticals+(SLXP)+as+Top+Small+Cap+Pick+for+2010/5217873.html GLTA Investor 100